Entecavir is used for: Chronic hepatitis B.
Recorded in the NepalDoc medicine catalog for Entecavir.
Entecavir tablets are indicated for the treatment of chronic hepatitis B virus infection in adults and pediatric patients 2 years of age and older with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease.
From the U.S. FDA-approved label for Entecavir. Full label: DailyMed.
Entecavir tablets are indicated for the treatment of chronic hepatitis B virus infection in adults and pediatric patients 2 years of age and older with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease.
From the U.S. FDA-approved label for Entecavir. Full label: DailyMed.
Nucleoside-inhibitor-treatment-naïve with compensated liver disease (greater than or equal to 16 years old): 0.5 mg once daily. Nucleoside-inhibitor-treatment-naïve and lamivudine-experienced pediatric patients at least 2 years of age and weighing at least 10 kg: dosing is based on weight. Lamivudine-refractory or known lamivudine or telbivudine resistance substitutions (greater than or equal to 16 years old): 1 mg once daily.
Directions from the U.S. FDA-approved label for Entecavir — your doctor or pharmacist may advise differently.
Severe acute exacerbations of hepatitis B virus infection after discontinuation: Monitor hepatic function closely for at least several months. Co-infection with HIV: Entecavir is not recommended unless the patient is also receiving HAART. Lactic acidosis and severe hepatomegaly with steatosis: If suspected, treatment should be suspended. 5.1 Severe Acute Exacerbations of Hepatitis B Severe acute exacerbations of hepatitis B have been reported in patients who have discontinued anti-hepatitis B therapy, including entecavir.
Warnings and precautions excerpt from the U.S. FDA-approved label for Entecavir — not a complete list. Talk to a pharmacist or doctor before use.
The following adverse reactions are discussed in other sections of the labeling: Exacerbations of hepatitis after discontinuation of treatment. Lactic acidosis and severe hepatomegaly with steatosis. In adults, the most common adverse reactions (≥3%, all severity grades) are headache, fatigue, dizziness, and nausea. The adverse reactions observed in pediatric patients were consistent with those observed in adults.
Excerpt from the U.S. FDA-approved label for Entecavir — not a complete list. Talk to a pharmacist or doctor about side effects.
7 brands · 6 makers in the NepalDoc catalog — see the full Entecavir guide →
Storage Entecavir tablets, USP should be stored in a tightly closed container at 20° to 25°C (68° to 77°F); Protect from light.
Storage information from the U.S. FDA-approved label for Entecavir.
What is Entavir 0.5?
Entavir 0.5mg Tablet is a Entecavir medicine made by Cipla Ltd. It comes as 0.5mg Tablet.
What is Entavir 0.5 used for?
Entecavir is used for Chronic hepatitis B.
What is the generic name of Entavir 0.5?
The generic name of Entavir 0.5 is Entecavir.
Which brands of Entecavir are available in Nepal?
7 brands of Entecavir are listed in the NepalDoc catalog, from 6 makers — including ACECAVIR 0.5mg Tablet, Entaliv 0.5mg Tablet, Enteca 0.5mg Tablet, Enteca 1mg Tablet, Gunavir Tablet, X-VIR 0.5mg Tablet.
What are the side effects of Entecavir?
The following adverse reactions are discussed in other sections of the labeling: Exacerbations of hepatitis after discontinuation of treatment. Lactic acidosis and severe hepatomegaly with steatosis. In adults, the most common adverse reactions (≥3%, all severity grades) are headache, fatigue, dizziness, and nausea.
This page is information only and is not medical advice. Medicine details come from the sources listed above and may change — always confirm the medicine, strength and dose with a pharmacist or doctor before use. A catalog listing does not guarantee that a medicine is in stock at any pharmacy.
